A newly-published educational tool will help guide users through a global consensus report about hyperglycaemia management in type 2 diabetes.
Trend Diabetes has developed the ‘Person-Centred Care in Type 2 Diabetes’ document to help users navigate the ‘Management of hyperglycaemia in type 2 diabetes: A consensus report’ by American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) due to the lack of updated guidance from NICE.
Published online, the Trend Diabetes document addresses each section of the evidence-based consensus where there is greater focus on person-related issues and self-management, which have a major impact on success of any pharmacological interventions.
The consensus document also gives choices of glucose-lowering medications supported by new evidence from cardiovascular outcomes trials and consideration of major clinical need.
The sections include:
- A decision cycle for person-centred glycaemic management in type 2 diabetes
- Glucose-lowering medication in type 2 diabetes
- Intensifying to injectable medication
- Continued use of oral medication when intensifying to injectable medication
Co-Founder and Co-Chair Debbie Hicks said: “The ADA/EASD Consensus document (2019) is used throughout the world to help improve the care of people with type 2 diabetes and importantly, support in preventing complications associated with type 2 diabetes such as myocardial infarction, stroke, renal failure, blindness and amputations.
“By utilising this treatment pathway, as early as possible, we can encourage engagement from the person with type 2 diabetes to understand what part they have to play in reducing the risk of complications in the future by understanding when and what medications are used to maintain the blood glucose level to near normal levels. “The newer therapies are instrumental in protecting people with type 2 diabetes from cardiovascular disease including heart failure but also protecting people from renal damage.”
Co-Founder and Co-Chair of Trend Diabetes, June James, said: “We are presenting the evidence-based treatment pathway for healthcare professionals who are treating people with type 2 diabetes. We hope those who use the tool find our approach useful and informative.
“We are all more aware now that the treatment of type 2 diabetes is much more than just managing glucose levels. We have emerging research relating to the new medications, namely the SGLT2 inhibitors and the GLP-1 RAs, showing us that these classes not only lower glucose levels but help with weight loss and protect people with type 2 diabetes against long term complications. Long term complications place an enormous burden on the individual experiencing them but also cost the NHS miilions of pounds each year.”
To access the document, click here.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.